Integer Holdings Corporation Lowers 2025 Sales Guidance, Stock Plummets 32.3%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations and undermining investor confidence.
- Declining Product Sales: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, indicating slower market adoption than anticipated.
- Stock Price Plunge: Following this news, Integer's stock price fell by $35.22, or 32.3%, closing at $73.89 on October 23, severely impacting investor interests.
- Class Action Initiated: Investors who purchased Integer stock between July 25, 2024, and October 22, 2025, and suffered losses can move to request appointment as lead plaintiff in the class action lawsuit by February 9, 2026, seeking legal recourse.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 84.700
Low
69.00
Averages
91.75
High
140.00
Current: 84.700
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
